INTRODUCTION
To coordinate their functions, cells must communicate with one other and with the extracellular matrix through specific molecules that transduce extracellular stimuli in intracellular signaling cascades. Receptor pathways do not function in isolation; indeed, signals from multiple receptors and the underlying cytoskeleton influence one other substantially. This crosstalk is illustrated by the connections between structurally distinct classes of receptors, such as G protein-coupled receptor (GPCR) and tyrosine kinase receptor (RTK).
The convergence of GPCR and RTK signaling pathways is supported by observations that platelet-derived growth factor, epidermal growth factor (EGFR) and type-1 insulin-like growth factor receptors (IGF-1R) are tyrosine phosphorylated after GPCR activation, and the mechanisms underlying this crosscommunication have begun to be understood (Rao et al., 1995; Prenzel et al., 1999) . Although transactivation of GPCR signaling by RTK is reported (Luttrell et al., 1995; Kanzaki et al., 1997) , it is controversial (Siebler et al., 1996) , as the mechanism underlying this crosstalk remains unknown.
Here we show that IGF-I, a growth factor that signals through an RTK, induces specific transactivation of the CCR5 chemokine receptor, a type of GPCR, through a mechanism involving the extracellular secretion of its natural ligand, RANTES. Our results also establish that CCR5 transactivation is an important step in IGF-I-triggered signaling, since abrogation of CCR5 function with the dominant-negative KDELccr5Δ32 mutant abolishes IGF-I-induced cell chemotaxis. In vivo tumor cell invasion may be enhanced or prevented by switching this transactivation pathway on or off. Extension of this model to basic fibroblast growth factor (bFGF) suggests that this extracellular growth factor-chemokine network may represent a prevalent feature of growth factor-triggered chemotactic signaling in malignant and untransformed cell lines.
RESULTS AND DISCUSSION
To study GPCR transactivation by RTK, we analyzed IGF-I-and chemokine-induced chemotactic responses in MCF-7 cells. MCF-7 cells respond chemotactically to IGF-I and poorly to β chemokines ( Figure 1A ). Pretreatment of MCF-7 cells with pertussis toxin (Ptx), a drug that inactivates G i by ADP ribosylation of the Gα subunit and hence inhibits β chemokine signaling, blocks chemotaxis induced by RANTES, a chemokine that binds the CCR5 chemokine receptor ( Figure 1A ). Ptx also inhibits scientific reports IGF-I-induced MCF-7 migration, suggesting that IGF-I activity requires downstream activation of a Ptx-sensitive GPCR.
We thus analyzed whether IGF-I stimulation of MCF-7 IGF-I promoted specific signaling events mediated by the chemokine receptors expressed by these cells. Chemokine receptors are tyrosine phosphorylated immediately after activation (Vila-Coro et al., 1999) and MCF-7 stimulation with RANTES-or SDF-1α (stromal cell-derived factor-1) induces time-dependent tyrosine phosphorylation of CCR5 ( Figure 1B ) or CXCR4 ( Figure 1C ), respectively. IGF-I stimulation induces tyrosine phosphorylation of CCR5 ( Figure 1B ), but not of other chemokine receptors such as CXCR4 ( Figure 1C ), indicating that IGF-I specifically transactivates CCR5. Compared to the rapid CCR5 phosphorylation that follows RANTES stimulation, IGF-I induces biphasic CCR5 activation, with a first phosphorylation peak at 15 min poststimulation and a second peak after 120 min ( Figure 1B ). This lag in IGF-I-mediated CCR5 transactivation is not due to a general delay in IGF-I-mediated responses, since the type-1 IGF receptor (IGF-1R) is activated by 1 min of IGF-I stimulation ( Figure 1B) . IGF-I stimulation also induces Gα i recruitment to the activated CCR5 ( Figure 1B ), but Gα i association to the IGF-1R was not observed (not shown). These data show that IGF-I stimulation transactivates CCR5 in a manner similar to activation by RANTES.
To characterize the molecular mechanisms by which IGF-I triggers specific CCR5 transactivation, we studied the effect of neutralizing anti-RANTES monoclonal antibodies (mAb) in this process. IGF-I-induced early CCR5 transactivation is prevented by adding anti-RANTES mAb (Figure 2A ) or by blocking protein secretion with monensin ( Figure 2B ); these treatments do not affect early IGF-1R signals such as receptor autophosphorylation (Figure 2A and B) . The requirement for extracellular RANTES secretion in IGF-I-induced signaling was confirmed, as both neutralizing anti-RANTES and anti-IGF-I mAb inhibit IGF-Imediated chemotaxis equally well ( Figure 2C ). Conversely, antagonist mAb against other chemokines such as MCP-1 
Fig. 2. IGF-I-induced CCR5 transactivation is dependent on RANTES
secretion. MCF-7 cells were stimulated with IGF-I alone or in the presence of anti-RANTES mAb (A), or preincubated with monensin before IGF-I stimulation (B). IGF-1R or CCR5 were selectively precipitated; Gα i recruitment to CCR5, or IGF-1R autophosphorylation (PY) were analyzed by western blotting. Membranes were reprobed with anti-CCR5 and -IGF-1R antibodies. For monensin treatment, western blot data are represented as the densitometry intensity ratio for Gα i and CCR5, or that calculated for tyrosinephosphorylated and total IGF-1R β-subunit (** p <0.001, two-tailed t-test). (C) IGF-I-induced MCF-7 chemotaxis was assayed in the presence of neutralizing anti-chemokine mAb. An isotype-matched non-specific (non-sp) and a blocking anti-IGF-I mAb were included as negative and positive controls, respectively. Results are expressed as a percentage, and indicate inhibition of chemotaxis in the presence of each antibody (n = 3; ** p <0.001, two-tailed t-test). (D) RANTES levels of cell-free supernatants from serumdepleted (-) and IGF-I (10 nM; +)-stimulated cells.
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(monocyte chemotactic protein-1), MIP-1α/β (macrophage inflammatory proteins-1α/β) or SDF-1α do not affect IGF-I activity ( Figure 2C ). This suggests that IGF-I-induced CCR5 transactivation is mediated by extracellular RANTES release. Concurring with this, IGF-I stimulation specifically increases RANTES levels ( Figure 2D ), but not those of MIP-1α/β, growth-related peptide (Groα), or MCP-1 (not shown) in MCF-7-conditioned medium.
To gain insight into IGF-I-mediated RANTES production, we analyzed its intracellular concentration. IGF-I induces a biphasic increase in intracellular RANTES, with the same kinetics as IGF-I-induced CCR5 transactivation ( Figure 3A) . The intracellular RANTES protein concentration correlates with RANTESencoding mRNA levels ( Figure 3B ). IGF-I increases the cellular content of RANTES mRNA by both a transcription-dependent and -independent effect, as actinomycin D does not affect the RANTES mRNA peak at 15 min, but abolishes the IGF-Imediated increase at longer stimulation times ( Figure 3B ). Accordingly, IGF-I treatment increases RANTES promoter-driven luciferase activity, whereas the MIP-1β promoter is unaffected ( Figure 3C ). The IGF-I-induced increase in the RANTES transcription rate was significant as early as 5 h, but augmented further at longer stimulation times. These results suggest that IGF-I-induced CCR5 transactivation is mediated by extracellular secretion of RANTES, which in turn binds to and activates CCR5. IGF-I regulates RANTES expression in MCF-7 cells in two discrete stages. First, IGF-I induces RANTES production by stabilizing RANTES mRNA or increasing its translation rate; the second phase involves specific upregulation of RANTES gene transcription by a direct or indirect IGF-I-mediated mechanism.
To study the functional relevance of IGF-I-induced CCR5 transactivation, cells were transduced with a CCR5 deletion mutant engineered to be retained in endoplasmic reticulum (KDELccr5Δ32), which is phenotypically similar to the natural ccr5Δ32 mutant (Liu et al., 1996) . Overexpression of KDELccr5Δ32 in MCF-7 cells specifically sequestered endogenous CCR5 (Figure 4A ), probably by forming heterocomplexes as reported for the ccr5Δ32 form (Benkirane et al., 1997) , thus acting as a CCR5 dominant-negative mutant. KDELccr5Δ32 overexpression drastically decreases IGF-I-induced chemotaxis ( Figure 4B ). IGF-I stimulation of mock-transduced cells induces acquisition of a polarized phenotype, shown here as focal scientific reports contact accumulation at the leading edge ( Figure 4C and D) , which is essential for IGF-I-induced MCF-7 chemotaxis (Mañes et al., 1999b) . Nonetheless, KDELccr5Δ32 overexpression incapacitates cell acquisition of this IGF-I-induced motile phenotype ( Figure 4C and D) . SDF-1α stimulation rescues both the enhanced chemotaxis observed with SDF-1α plus IGF-I ( Figure 4B ) and acquisition of the polarized phenotype in KDELccr5Δ32-expressing cells ( Figure 4C and D) . KDELccr5Δ32 thus inhibits IGF-I chemotaxis by specific CCR5 sequestration, rendering the cell unable to respond to the RANTES secreted; indeed, RANTES-induced MCF-7 polarization is lost in KDELccr5Δ32-expressing cells. These results establish that CCR5 transactivation is a downstream target activated by autocrine RANTES, required for IGF-I-induced cell polarization and chemotaxis. We also observed that bFGF-induced BAEC chemotaxis is dependent on CCR2 transactivation (see Supplementary material Online), suggesting that growth factor-induced chemokine secretion may be a prevalent feature of RTK-triggered chemotactic signaling.
We tested whether abrogation of CCR5 function prevents in vivo tumor invasion of IGF-I-dependent cell lines. We overexpressed KDELccr5Δ32 in DU-145 cells, a highly invasive prostate carcinoma with a well-characterized IGF-I autocrine loop (Mañes et al., 1999a) . In addition to IGF-I, DU-145 cells secrete high RANTES levels without exogenous stimulation ( Figure 5A ), and IGF-1R and CCR5 are constitutively activated in DU-145 (Mañes et al., 1999a) . KDELccr5Δ32 overexpression reduces IGF-I-and RANTES-induced DU-145 chemotaxis in vitro (not shown), indicating that this mutant sequesters CCR5 in DU-145, as it does in MCF-7.
To assay the role of CCR5 in tumor invasion, we seeded mockand KDELccr5Δ32-transduced DU-145 cells onto chick embryo chorioallantoic membrane (CAM). The mean number of KDELccr5Δ32-DU-145 cells recovered in the lower CAM was up to 80% lower than that of mock-transduced cells, indicating that KDELccr5Δ32 overexpression prevents DU-145 cell invasiveness in the CAM model ( Figure 5B ; p <0.05). To study whether CCR5 signals modulate tumor invasiveness, mocktransduced and MCF-7 cells overexpressing RANTES were analyzed in the CAM assay. MCF-7 cells were non-invasive (Kim et al., 1998) and secreted no detectable RANTES in unstimulated conditions ( Figure 2D) ; indeed, very few mock-transduced MCF-7 cells reach the lower CAM ( Figure 5C ). RANTES overexpression increases the number of MCF-7 cells recovered from the lower CAM by >10-fold ( Figure 5C ; p <0.05).
Our findings distinguish extracellular chemokine secretion as a pivotal RTK signal, and extend understanding of the pathways leading to many growth factor-regulated biological processes. RTK-induced chemokine secretion is identified in tumor and untransformed cells, as both cell types invade tissues using identical molecular strategies. This leads us to propose that this growth factor-chemokine network represents a general mechanism of broad physiological significance.
Previous data suggested that RTK-induced GPCR transactivation was mediated exclusively through intracellular signals (Hallak et al., 2000) . Although constitutive Gα i binding to the IGF-1R has been reported, this association does not explain the mechanism by which RTK transactivates GPCR. Further, Gα i is not a substrate for IGF-1R kinase activity. Our data indicate that IGF-I-induced GPCR transactivation involves two transmembrane signaling events: first, growth factor-induced RTK activation triggers extracellular release of a GPCR ligand and secondly, the released ligand binds to and activates the GPCR in an autocrine/paracrine manner. A similar mechanism was recently proposed to explain RTK transactivation by GPCR receptors. GPCR-induced EGFR transactivation involves EGF precursor release from the membrane, which in turn binds to and activates the EGFR (Prenzel et al., 1999) . Taken together, these data indicate that crosstalk between RTK and GPCR uses an extracellular crosscommunication mechanism that may operate in both directions.
SPECULATION
The growth factor-induced CCR5 transactivation described here reveals a mechanism that links chronic inflammation and tumorigenesis. Our results in the CAM model suggest that CCR5 signals modulate the in vivo invasiveness of tumor cells. In addition, the upregulation of RANTES gene expression has been detected in invasive human breast carcinomas (Sgroi et al., 1999) . As constitutive growth factor secretion is observed in invasive tumor cells, it is tempting to speculate that this may increase proinflammatory chemokine concentration in the environment, providing the cells with a built-in invasive capacity. Comparative study of DU-145 and MCF-7 cells suggests a link between autocrine production of growth factors (IGF-I) and chemokines (RANTES), which correlates to their invasive capacity. Detailed study of this coordinated signaling circuit may thus provide insights into the onset of tumor invasion, as well as potential tools for clinical intervention. 
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METHODS
Cell culture. MCF-7 human breast carcinoma cells (ATCC, were maintained in MEM with 10% FCS, antibiotics and non-essential amino acids. Bovine aortic endothelial cells (BAEC), kindly provided by M. Grandi (Pharmacia, Nerviano, Italy), and DU-145 human prostate adenocarcinoma (ATCC, HTB-81) were cultured in DMEM with 10% FCS and antibiotics. Immunoprecipitation, western blot and immunofluorescence. Serum-starved MCF-7 cells were stimulated with IGF-I (50 ng/ ml, Pharmacia), RANTES or SDF-1α (both 10 ng/ml; R&D Systems), lysed and CCR5, CXCR4 and IGF-1R were precipitated with specific mAb followed by agarose-anti-mouse IgG (Sigma). Tyrosine phosphorylated proteins were detected with 4G10 mAb (UBI), Gα i with C20, and the IGF-1R β-subunit with C20 (both from Santa Cruz). In some cases, anti-RANTES antagonist mAb (10 μg/ml; R&D Systems) was added simultaneously with IGF-I. To block protein secretion, MCF-7 cells were incubated with monensin (0.5 μM, 30 min, 37°C; Sigma), cells washed with serum-free medium, then IGF-I stimulated. Immunofluorescence analyses were as reported (Mañes et al., 1999b) on cells stimulated with IGF-I (10 ng/ml) or SDF-1α (10 ng/ml) (20 min, 37°C). Estimation of RANTES protein levels. Chemokine levels in conditioned media or in RIPA cell lysates (50 μg) from IGF-I-or serum-starved MCF-7 cells were assessed by specific ELISA (R&D Systems; BioSource). Measurement of RANTES mRNA levels and transcription assays. MCF-7 cells were incubated with IGF-I (10 nM) alone or with actinomycin D (5 μg/ml). mRNA coding for RANTES was specifically measured by semiquantitative PCR in a LightCycler System (Roche Diagnostics), RANTES mRNA levels were normalized with those for GAPDH mRNA.
For the IGF-I effect on the RANTES transcription rate, MCF-7 cells were transiently transfected with RANTES and MIP-1β promoters (from W.J. Leonard, NIH, Bethesda, MD) and promoter-less (pEFBOS-luc from D. Wotton; University of Virginia, Charlottesville, VA) luciferase reporter gene constructs, and the activity measured using luciferase assay reagent (Promega) in a luminometer. Cloning and viral transduction. The bicistronic retroviral vector pLZIRES-gfp was derived from pLZR-CMV-gfp (R. Delgado, Hospital 12 Octubre, Madrid, Spain). The KDELccrΔ32 mutant, obtained from an hCCR5 cDNA clone, was subcloned in pLZIRES-gfp. Human RANTES was similarly cloned to obtain pLZ-RANTES-IRES-gfp. For viral transduction, MCF-7 or DU-145 (10 6 cells) were incubated with retroviral pLZ-RANTES-IRES-gfp, pLZ-KDELccr5Δ32-IRES-gfp or pLZIRES-gfp (mock) supernatants in protamine sulphate (5 μg/ml, 14 h, 37°C), and cells expressing GFP were selected 72 h after infection by fluorescence-activated cell sorting. Chemokine receptor levels in KDELccr5Δ32-transduced cells were evaluated by flow cytometry with anti-CCR2, -CCR5 (from M. Mellado and J.M. Rodríguez-Frade, DIO/CNB, Madrid, Spain) and -CXCR4 (R&D Systems). Cell migration assays. MCF-7 and BAEC chemotaxis was performed as described (Mañes et al., 1999b) using IGF-I (1 ng/ml), bFGF (50 ng/ml), RANTES (1-40 ng/ml), SDF-1α (10-100 ng/ml), or combinations of these as chemoattractants. In some cases, cells were preincubated with neutralizing anti-RANTES, -SDF-1α, -MCP-1, or -MIP-1α/β mAb (all from R&D Systems) for 30 min before transwell seeding, or pretreated with Ptx (1 μg/ml, 8 h, 37°C), which was removed before the chemotaxis assay. Intravasation experiments were as described (Kim et al., 1998) and human DNA present in the chicken CAM estimated by PCR in a LightCycler System with human Alu sequence-specific primers. A standard curve of serial dilutions of human DNA mixed with chicken DNA was obtained in each determination. The relative value of human DNA in CAM samples was calculated by the quantification software provided with the apparatus. The number of human cells in each DNA sample (30 ng) was calculated assuming 6 pg/cell of DNA. Supplementary data. Supplementary data are available at EMBO reports Online.
